Ypsomed Holding
 | |
Native name | Ypsomed Holding AG |
|---|---|
| Company type | Public |
| Industry | Medical technology |
| Founded | 2003 |
| Founder | Willy Michel |
| Headquarters | Switzerland  |
Key people | Gilbert Achermann (Chairman Simon Michel (CEO) |
| Revenue |  US$928.3 million (2024) |
Number of employees | 2,800 (2025) |
| Website | ypsomed |
Ypsomed Holding Inc. (German pronunciation: [ˈʏp.soː.mɛd]) is a Swiss multinational medical technology company headquartered in Burgdorf, Switzerland.[1] Founded in 2003, through the break up of Disetronic Group, founded by Willy Michel.[2][3][4] Ypsomed specializes in developing and manufacturing injection and infusion systems for self-medication, primarily in the areas of diabetes care and biotechnology.[5]
Products include devices like insulin pens, auto-injectors, and infusion pumps, which help patients manage chronic conditions more easily and independently. In 2025, Ypsomed employs 2,800+ employees and has an annual turnover of 728.9 million Swiss Francs ($928.3 million). The company is listed on SIX Swiss Exchange.[6]
References
- ^ AG, DV Bern. "Ypsomed Holding AG". Commercial register of canton Bern. Retrieved 2025-08-07.
- ^ "Willy Michel". Forbes. Retrieved 2025-08-07.
- ^ swissinfo.ch, S. W. I. (2005-10-28). "Ypsomed chairman named Master Entrepreneur". SWI swissinfo.ch. Retrieved 2025-08-07.
- ^ "Simon Michel - Ypsomed | Swiss Politics & Running a Large Medtech Business". www.swisspreneur.org. Retrieved 2025-08-07.
- ^ J, Plattform. "«Wir müssen den bilateralen Weg stabilisieren und weiterentwickeln» - Plattform J". www.plattformj.ch (in German). Retrieved 2025-08-07.
- ^ "Investors - Ypsomed". www.ypsomed.com. Retrieved 2025-08-07.